Eli Lilly's new offering of Zepbound in vials at significantly lower prices compared to its injectable pens reflects its commitment to improve access for obesity treatments.
While Lilly's new pricing structure garnered praise, their silent price increase on existing forms of the drug sparked criticism, highlighting concerns over transparency.
James Zervos stated, "Expanding coverage and affordability of treatments is vital to people living with obesity... we commend Lilly for their leadership in offering an innovative solution."
The crucial difference in efficacy between dosage levels raises questions about the alignment of pricing strategies with actual treatment outcomes for patients.
Collection
[
|
...
]